Improving drug delivery to solid tumors: Priming the tumor microenvironment

Journal of Controlled Release

Volumn 201, Issue , 2015, Pages 78-89

  Khawar, Iftikhar Ali ^a   Kim, Jung Ho ^a   Kuh, Hyo Jeong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Drug efficacy; Solid stress; Tumor microenvironment; Tumor priming; Tumor stroma; Vascular normalization

Indexed keywords

CARDIOVASCULAR SYSTEM; DRUG DELIVERY; DRUG THERAPY; ENZYME ACTIVITY; ENZYME INHIBITION;

DRUG EFFICACY; SOLID STRESS; TUMOR MICROENVIRONMENT; TUMOR-STROMA; VASCULAR NORMALIZATION;

TUMORS;

ANTINEOPLASTIC AGENT;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STEM CELL; CHEMOSENSITIVITY; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TRANSPORT; EXTRACELLULAR MATRIX; HUMAN; HYDRAULIC CONDUCTIVITY; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84921711123     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.12.018     Document Type: Review

References (152)

1. I.F. Tannock, C.M. Lee, J.K. Tunggal, D.S. Cowan, and M.J. Egorin Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy Clin. Cancer Res. 8 2002 878 884
2. A.H. Kyle, L.A. Huxham, D.M. Yeoman, and A.I. Minchinton Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors Clin. Cancer Res. 13 2007 2804 2810
3. O. Tredan, C.M. Galmarini, K. Patel, and I.F. Tannock Drug resistance and the solid tumor microenvironment J. Natl. Cancer Inst. 99 2007 1441 1454
4. V.P. Chauhan, T. Stylianopoulos, Y. Boucher, and R.K. Jain Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies Annu. Rev. Chem. Biomol. Eng. 2 2011 281 298
5. I.F. Tannock The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour Br. J. Cancer 22 1968 258 273
6. A. Nacev, S.H. Kim, J. Rodriguez-Canales, M.A. Tangrea, B. Shapiro, and M.R. Emmert-Buck A dynamic magnetic shift method to increase nanoparticle concentration in cancer metastases: a feasibility study using simulations on autopsy specimens Int. J. Nanomedicine 6 2011 2907 2923
7. A.I. Minchinton, and I.F. Tannock Drug penetration in solid tumours Nat. Rev. Cancer 6 2006 583 592
8. A.J. Primeau, A. Rendon, D. Hedley, L. Lilge, and I.F. Tannock The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors Clin. Cancer Res. 11 2005 8782 8788
9. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
10. S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, and R.K. Jain Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proc. Natl. Acad. Sci. U. S. A. 95 1998 4607 4612
11. A. Ozcelikkale, S. Ghosh, and B. Han Multifaceted transport characteristics of nanomedicine: needs for characterization in dynamic environment Mol. Pharm. 10 2013 2111 2126
12. H. Maeda Macromolecular therapeutics in cancer treatment: the EPR effect and beyond J. Control. Release 164 2012 138 144
13. L.Y. Rizzo, B. Theek, G. Storm, F. Kiessling, and T. Lammers Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications Curr. Opin. Biotechnol. 24 2013 1159 1166
14. E. Cukierman, and D.R. Khan The benefits and challenges associated with the use of drug delivery systems in cancer therapy Biochem. Pharmacol. 80 2010 762 770
15. V.P. Torchilin Targeted pharmaceutical nanocarriers for cancer therapy and imaging AAPS J. 9 2007 E128 E147
16. V.P. Torchilin Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery Nat. Rev. Drug Discov. 13 2014 813 827
17. A.A. Gabizon Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet Clin. Cancer Res. 7 2001 223 225
18. A.L. Klibanov, K. Maruyama, V.P. Torchilin, and L. Huang Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett. 268 1990 235 237
19. J. Fang, T. Sawa, T. Akaike, T. Akuta, S.K. Sahoo, G. Khaled, A. Hamada, and H. Maeda In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor Cancer Res. 63 2003 3567 3574
20. T. Lammers, F. Kiessling, W.E. Hennink, and G. Storm Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Control. Release 161 2012 175 187
21. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. Oncol. 19 2001 3312 3322
22. D.W. Northfelt, B.J. Dezube, J.A. Thommes, B.J. Miller, M.A. Fischl, A. Friedman-Kien, L.D. Kaplan, C.Du. Mond, R.D. Mamelok, and D.H. Henry Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial J. Clin. Oncol. 16 1998 2445 2451
23. M.E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D.G. Kieback, P. Tomczak, S.P. Ackland, F. Orlandi, L. Mellars, L. Alland, and C. Tendler Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 2004 440 449
24. P.S. Gill, J. Wernz, D.T. Scadden, P. Cohen, G.M. Mukwaya, J.H. von Roenn, M. Jacobs, S. Kempin, I. Silverberg, G. Gonzales, M.U. Rarick, A.M. Myers, F. Shepherd, C. Sawka, M.C. Pike, and M.E. Ross Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma J. Clin. Oncol. 14 1996 2353 2364
25. W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and J. O'Shaughnessy Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 23 2005 7794 7803
26. R.K. Jain, and T. Stylianopoulos Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 7 2010 653 664
27. V.P. Chauhan, and R.K. Jain Strategies for advancing cancer nanomedicine Nat. Mater. 12 2013 958 962
28. M. Dellian, F. Yuan, V.S. Trubetskoy, V.P. Torchilin, and R.K. Jain Vascular permeability in a human tumour xenograft: molecular charge dependence Br. J. Cancer 82 2000 1513 1518
29. F. Yuan, M. Leunig, S.K. Huang, D.A. Berk, D. Papahadjopoulos, and R.K. Jain Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res. 54 1994 3352 3356
30. S. Strieth, M.E. Eichhorn, B. Sauer, B. Schulze, M. Teifel, U. Michaelis, and M. Dellian Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature Int. J. Cancer 110 2004 117 124
31. H. Hatakeyama, H. Akita, and H. Harashima A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Deliv. Rev. 63 2011 152 160
32. T.A. Denison, and Y.H. Bae Tumor heterogeneity and its implication for drug delivery J. Control. Release 164 2012 187 191
33. Y.H. Bae, and K. Park Targeted drug delivery to tumors: myths, reality and possibility J. Control. Release 153 2011 198 205
34. A.S. Mikhail, S. Eetezadi, S.N. Ekdawi, J. Stewart, and C. Allen Image-based analysis of the size- and time-dependent penetration of polymeric micelles in multicellular tumor spheroids and tumor xenografts Int. J. Pharm. 464 2014 168 177
35. H. Kobayashi, R. Watanabe, and P.L. Choyke Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 4 2013 81 89
36. U. Prabhakar, H. Maeda, R.K. Jain, E.M. Sevick-Muraca, W. Zamboni, O.C. Farokhzad, S.T. Barry, A. Gabizon, P. Grodzinski, and D.C. Blakey Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology Cancer Res. 73 2013 2412 2417
37. J.N. Weinstein, and W. van Osdol Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier" Cancer Res. 52 9 Suppl. 1992 2747s 2751s
38. I.K. Kwon, S.C. Lee, B. Han, and K. Park Analysis on the current status of targeted drug delivery to tumors J. Control. Release 164 2012 108 114
39. F.C. Galmarini, C.M. Galmarini, M.I. Sarchi, J. Abulafia, and D. Galmarini Heterogeneous distribution of tumor blood supply affects the response to chemotherapy in patients with head and neck cancer Microcirculation 7 6 Pt 1 2000 405 410
40. M. Egeblad, E.S. Nakasone, and Z. Werb Tumors as organs: complex tissues that interface with the entire organism Dev. Cell 18 2010 884 901
41. R.K. Jain Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers J. Clin. Oncol. 31 2013 2205 2218
42. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
43. S. Morikawa, P. Baluk, T. Kaidoh, A. Haskell, R.K. Jain, and D.M. McDonald Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors Am. J. Pathol. 160 2002 985 1000
44. P. Baluk, S. Morikawa, A. Haskell, M. Mancuso, and D.M. McDonald Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors Am. J. Pathol. 163 2003 1801 1815
45. R.K. Jain Determinants of tumor blood flow: a review Cancer Res. 48 1988 2641 2658
46. R.K. Jain Delivery of molecular and cellular medicine to solid tumors Adv. Drug Deliv. Rev. 46 2001 149 168
47. G. Bergers, and S. Song The role of pericytes in blood-vessel formation and maintenance Neuro Oncol. 7 2005 452 464
48. R.K. Jain, and M.F. Booth What brings pericytes to tumor vessels? J. Clin. Invest. 112 2003 1134 1136
49. S. Goel, D.G. Duda, L. Xu, L.L. Munn, Y. Boucher, D. Fukumura, and R.K. Jain Normalization of the vasculature for treatment of cancer and other diseases Physiol. Rev. 91 2011 1071 1121
50. R.K. Jain Transport of molecules in the tumor interstitium: a review Cancer Res. 47 1987 3039 3051
51. M. Milosevic, A. Fyles, D. Hedley, and R. Hill The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure Semin. Radiat. Oncol. 14 2004 249 258
52. P.P. Provenzano, C. Cuevas, A.E. Chang, V.K. Goel, D.D. Von Hoff, and S.R. Hingorani Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma Cancer Cell 21 2012 418 429
53. M.A. Jacobetz, D.S. Chan, A. Neesse, T.E. Bapiro, N. Cook, K.K. Frese, C. Feig, T. Nakagawa, M.E. Caldwell, H.I. Zecchini, M.P. Lolkema, P. Jiang, A. Kultti, C.B. Thompson, D.C. Maneval, D.I. Jodrell, G.I. Frost, H.M. Shepard, J.N. Skepper, and D.A. Tuveson Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer Gut 62 2013 112 120
54. C.H. Heldin, K. Rubin, K. Pietras, and A. Ostman High interstitial fluid pressure - an obstacle in cancer therapy Nat. Rev. Cancer 4 2004 806 813
55. F. Danhier, O. Feron, and V. Preat To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery J. Control. Release 148 2010 135 146
56. E.H. Starling On the absorption of fluids from the connective tissue spaces J. Physiol. 19 1896 312 326
57. R.K. Jain, and L.T. Baxter Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure Cancer Res. 48 24 Pt 1 1988 7022 7032
58. M. Yu, and I.F. Tannock Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell 21 2012 327 329
59. R.K. Jain, J.D. Martin, and T. Stylianopoulos The role of mechanical forces in tumor growth and therapy Annu. Rev. Biomed. Eng. 16 2014 321 346
60. E.K. Rofstad, S.H. Tunheim, B. Mathiesen, B.A. Graff, E.F. Halsor, K. Nilsen, and K. Galappathi Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts Cancer Res. 62 2002 661 664
61. S. Kippenberger, A. Bernd, S. Loitsch, M. Guschel, J. Muller, J. Bereiter-Hahn, and R. Kaufmann Signaling of mechanical stretch in human keratinocytes via MAP kinases J. Investig. Dermatol. 114 2000 408 412
62. S. Kippenberger, S. Loitsch, M. Guschel, J. Muller, Y. Knies, R. Kaufmann, and A. Bernd Mechanical stretch stimulates protein kinase B/Akt phosphorylation in epidermal cells via angiotensin II type 1 receptor and epidermal growth factor receptor J. Biol. Chem. 280 2005 3060 3067
63. M. Hofmann, M. Schultz, A. Bernd, J. Bereiter-Hahn, R. Kaufmann, and S. Kippenberger Long-term lowering of tumour interstitial fluid pressure reduces Ki-67 expression J. Biomech. 40 2007 2324 2329
64. T.P. Padera, B.R. Stoll, J.B. Tooredman, D. Capen, E. di Tomaso, and R.K. Jain Pathology: cancer cells compress intratumour vessels Nature 427 2004 695
65. T. Stylianopoulos, J.D. Martin, M. Snuderl, F. Mpekris, S.R. Jain, and R.K. Jain Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse Cancer Res. 73 2013 3833 3841
66. T. Stylianopoulos, J.D. Martin, V.P. Chauhan, S.R. Jain, B. Diop-Frimpong, N. Bardeesy, B.L. Smith, C.R. Ferrone, F.J. Hornicek, Y. Boucher, L.L. Munn, and R.K. Jain Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors Proc. Natl. Acad. Sci. U. S. A. 109 2012 15101 15108
67. D. Lu, M.G. Wientjes, Z. Lu, and J.L. Au Tumor priming enhances delivery and efficacy of nanomedicines J. Pharmacol. Exp. Ther. 322 2007 80 88
68. Q. Li, A. Hata, C. Kosugi, N. Kataoka, and M. Funaki The density of extracellular matrix proteins regulates inflammation and insulin signaling in adipocytes FEBS Lett. 584 2010 4145 4150
69. M. Egeblad, M.G. Rasch, and V.M. Weaver Dynamic interplay between the collagen scaffold and tumor evolution Curr. Opin. Cell Biol. 22 2010 697 706
70. P. Lu, V.M. Weaver, and Z. Werb The extracellular matrix: a dynamic niche in cancer progression J. Cell Biol. 196 2012 395 406
71. F.X. Maquart, G. Bellon, S. Pasco, and J.C. Monboisse Matrikines in the regulation of extracellular matrix degradation Biochimie 87 2005 353 360
72. D.M. Gilkes, G.L. Semenza, and D. Wirtz Hypoxia and the extracellular matrix: drivers of tumour metastasis Nat. Rev. Cancer 14 2014 430 439
73. C. Frantz, K.M. Stewart, and V.M. Weaver The extracellular matrix at a glance J. Cell Sci. 123 2010 4195 4200
74. M. Fang, J. Yuan, C. Peng, and Y. Li Collagen as a double-edged sword in tumor progression Tumour Biol. 35 2014 2871 2882
75. J. Choi, K. Credit, K. Henderson, R. Deverkadra, Z. He, H. Wiig, H. Vanpelt, and M.F. Flessner Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration Clin. Cancer Res. 12 2006 1906 1912
76. A. Erikson, H.N. Andersen, S.N. Naess, P. Sikorski, and L. Davies Cde Physical and chemical modifications of collagen gels: impact on diffusion Biopolymers 89 2008 135 143
77. P.A. Netti, D.A. Berk, M.A. Swartz, A.J. Grodzinsky, and R.K. Jain Role of extracellular matrix assembly in interstitial transport in solid tumors Cancer Res. 60 2000 2497 2503
78. R.S. Turley, A.N. Fontanella, J.C. Padussis, H. Toshimitsu, Y. Tokuhisa, E.H. Cho, G. Hanna, G.M. Beasley, C.K. Augustine, M.W. Dewhirst, and D.S. Tyler Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma Clin. Cancer Res. 18 2012 3328 3339
79. H. Wildiers, G. Guetens, G. De Boeck, E. Verbeken, B. Landuyt, W. Landuyt, E.A. de Bruijn, and A.T. van Oosterom Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 Br. J. Cancer 88 2003 1979 1986
80. J.P. Ritchie, V.C. Ramani, Y. Ren, A. Naggi, G. Torri, B. Casu, S. Penco, C. Pisano, P. Carminati, M. Tortoreto, F. Zunino, I. Vlodavsky, R.D. Sanderson, and Y. Yang SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis Clin. Cancer Res. 17 2011 1382 1393
81. R.T. Tong, Y. Boucher, S.V. Kozin, F. Winkler, D.J. Hicklin, and R.K. Jain Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res. 64 2004 3731 3736
82. A.V. Salnikov, V.V. Iversen, M. Koisti, C. Sundberg, L. Johansson, L.B. Stuhr, M. Sjoquist, H. Ahlstrom, R.K. Reed, and K. Rubin Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy FASEB J. 17 2003 1756 1758
83. K. Pietras, K. Rubin, T. Sjoblom, E. Buchdunger, M. Sjoquist, C.H. Heldin, and A. Ostman Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy Cancer Res. 62 2002 5476 5484
84. L. Eikenes, O.S. Bruland, C. Brekken, and L. Davies Cde Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts Cancer Res. 64 2004 4768 4773
85. L. Eikenes, M. Tari, I. Tufto, O.S. Bruland, and C. de Lange Davies Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts Br. J. Cancer 93 2005 81 88
86. T.T. Goodman, P.L. Olive, and S.H. Pun Increased nanoparticle penetration in collagenase-treated multicellular spheroids Int. J. Nanomedicine 2 2007 265 274
87. M. Magzoub, S. Jin, and A.S. Verkman Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin FASEB J. 22 2008 276 284
88. L. Eikenes, I. Tufto, E.A. Schnell, A. Bjorkoy, and C. De Lange Davies Effect of collagenase and hyaluronidase on free and anomalous diffusion in multicellular spheroids and xenografts Anticancer Res. 30 2010 359 368
89. J. Liu, S. Liao, B. Diop-Frimpong, W. Chen, S. Goel, K. Naxerova, M. Ancukiewicz, Y. Boucher, R.K. Jain, and L. Xu TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma Proc. Natl. Acad. Sci. U. S. A. 109 2012 16618 16623
90. V.P. Chauhan, J.D. Martin, H. Liu, D.A. Lacorre, S.R. Jain, S.V. Kozin, T. Stylianopoulos, A.S. Mousa, X. Han, P. Adstamongkonkul, Z. Popovic, P. Huang, M.G. Bawendi, Y. Boucher, and R.K. Jain Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels Nat. Commun. 4 2013 2516
91. M. Loeffler, J.A. Kruger, A.G. Niethammer, and R.A. Reisfeld Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake J. Clin. Invest. 116 2006 1955 1962
92. K.P. Olive, M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M.A. Goldgraben, M.E. Caldwell, D. Allard, K.K. Frese, G. Denicola, C. Feig, C. Combs, S.P. Winter, H. Ireland-Zecchini, S. Reichelt, W.J. Howat, A. Chang, M. Dhara, L. Wang, F. Ruckert, R. Grutzmann, C. Pilarsky, K. Izeradjene, S.R. Hingorani, P. Huang, S.E. Davies, W. Plunkett, M. Egorin, R.H. Hruban, N. Whitebread, K. McGovern, J. Adams, C. Iacobuzio-Donahue, J. Griffiths, and D.A. Tuveson Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
93. K.N. Sugahara, T. Teesalu, P.P. Karmali, V.R. Kotamraju, L. Agemy, O.M. Girard, D. Hanahan, R.F. Mattrey, and E. Ruoslahti Tissue-penetrating delivery of compounds and nanoparticles into tumors Cancer Cell 16 2009 510 520
94. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151
95. K.O. Hicks, F.B. Pruijn, T.W. Secomb, M.P. Hay, R. Hsu, J.M. Brown, W.A. Denny, M.W. Dewhirst, and W.R. Wilson Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs J. Natl. Cancer Inst. 98 2006 1118 1128
96. S. Goel, A.H. Wong, and R.K. Jain Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease Cold Spring Harb. Perspect. Med. 2 2012 a006486
97. C. Pisano, I. Vlodavsky, N. Ilan, and F. Zunino The potential of heparanase as a therapeutic target in cancer Biochem. Pharmacol. 89 2014 12 19
98. J. Ma, C.S. Chen, T. Blute, and D.J. Waxman Antiangiogenesis enhances intratumoral drug retention Cancer Res. 71 2011 2675 2685
99. M.L. Salgaller Technology evaluation: bevacizumab, Genentech/Roche Curr. Opin. Mol. Ther. 5 2003 657 667
100. F. Fan, A. Schimming, D. Jaeger, and K. Podar Targeting the tumor microenvironment: focus on angiogenesis J. Oncol. 2012 2012 281261
101. Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, and R.K. Jain Tumour biology: herceptin acts as an anti-angiogenic cocktail Nature 416 2002 279 280
102. E.V. Rosca, J.E. Koskimaki, C.G. Rivera, N.B. Pandey, A.P. Tamiz, and A.S. Popel Anti-angiogenic peptides for cancer therapeutics Curr. Pharm. Biotechnol. 12 2011 1101 1116
103. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Haussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, J. Bruix, and S.I.S. Group Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 359 2008 378 390
104. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Negrier, C. Chevreau, E. Solska, A.A. Desai, F. Rolland, T. Demkow, T.E. Hutson, M. Gore, S. Freeman, B. Schwartz, M. Shan, R. Simantov, R.M. Bukowski, and T.S. Group Sorafenib in advanced clear-cell renal-cell carcinoma N. Engl. J. Med. 356 2007 125 134
105. C.G. Lee, M. Heijn, E. di Tomaso, G. Griffon-Etienne, M. Ancukiewicz, C. Koike, K.R. Park, N. Ferrara, R.K. Jain, H.D. Suit, and Y. Boucher Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res. 60 2000 5565 5570
106. S.V. Kozin, Y. Boucher, D.J. Hicklin, P. Bohlen, R.K. Jain, and H.D. Suit Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts Cancer Res. 61 2001 39 44
107. K. Pietras, J. Pahler, G. Bergers, and D. Hanahan Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting PLoS Med. 5 2008 e19
108. C. Anderberg, H. Li, L. Fredriksson, J. Andrae, C. Betsholtz, X. Li, U. Eriksson, and K. Pietras Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts Cancer Res. 69 2009 369 378
109. A.G. Sorensen, T.T. Batchelor, W.T. Zhang, P.J. Chen, P. Yeo, M. Wang, D. Jennings, P.Y. Wen, J. Lahdenranta, M. Ancukiewicz, E. di Tomaso, D.G. Duda, and R.K. Jain A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res. 69 2009 5296 5300
110. T.D. Tailor, G. Hanna, P.S. Yarmolenko, M.R. Dreher, A.S. Betof, A.B. Nixon, I. Spasojevic, and M.W. Dewhirst Effect of pazopanib on tumor microenvironment and liposome delivery Mol. Cancer Ther. 9 2010 1798 1808
111. V.P. Chauhan, T. Stylianopoulos, J.D. Martin, Z. Popovic, O. Chen, W.S. Kamoun, M.G. Bawendi, D. Fukumura, and R.K. Jain Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner Nat. Nanotechnol. 7 2012 383 388
112. G. Griffon-Etienne, Y. Boucher, C. Brekken, H.D. Suit, and R.K. Jain Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications Cancer Res. 59 1999 3776 3782
113. S.H. Jang, M.G. Wientjes, and J.L. Au Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule J. Pharmacol. Exp. Ther. 296 2001 1035 1042
114. Y. Li, J. Wang, M.G. Wientjes, and J.L. Au Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor Adv. Drug Deliv. Rev. 64 2012 29 39
115. M. Tsai, Z. Lu, M.G. Wientjes, and J.L. Au Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics J. Control. Release 172 2013 737 744
116. R. Tong, H.H. Chiang, and D.S. Kohane Photoswitchable nanoparticles for in vivo cancer chemotherapy Proc. Natl. Acad. Sci. U. S. A. 110 2013 19048 19053
117. E. Brown, T. McKee, E. diTomaso, A. Pluen, B. Seed, Y. Boucher, and R.K. Jain Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation Nat. Med. 9 2003 796 800
118. E.N. Unemori, and E.P. Amento Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts J. Biol. Chem. 265 1990 10681 10685
119. R. Masterson, T.D. Hewitson, K. Kelynack, M. Martic, L. Parry, R. Bathgate, I. Darby, and G. Becker Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro Nephrol. Dial. Transplant. 19 2004 544 552
120. S. Feng, I.U. Agoulnik, N.V. Bogatcheva, A.A. Kamat, B. Kwabi-Addo, R. Li, G. Ayala, M.M. Ittmann, and A.I. Agoulnik Relaxin promotes prostate cancer progression Clin. Cancer Res. 13 2007 1695 1702
121. K.R. Levental, H. Yu, L. Kass, J.N. Lakins, M. Egeblad, J.T. Erler, S.F. Fong, K. Csiszar, A. Giaccia, W. Weninger, M. Yamauchi, D.L. Gasser, and V.M. Weaver Matrix crosslinking forces tumor progression by enhancing integrin signaling Cell 139 2009 891 906
122. V. Barry-Hamilton, R. Spangler, D. Marshall, S. McCauley, H.M. Rodriguez, M. Oyasu, A. Mikels, M. Vaysberg, H. Ghermazien, C. Wai, C.A. Garcia, A.C. Velayo, B. Jorgensen, D. Biermann, D. Tsai, J. Green, S. Zaffryar-Eilot, A. Holzer, S. Ogg, D. Thai, G. Neufeld, P. Van Vlasselaer, and V. Smith Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment Nat. Med. 16 2010 1009 1017
123. P. Cirri, and P. Chiarugi Cancer associated fibroblasts: the dark side of the coin Am. J. Cancer Res. 1 2011 482 497
124. B. Diop-Frimpong, V.P. Chauhan, S. Krane, Y. Boucher, and R.K. Jain Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors Proc. Natl. Acad. Sci. U. S. A. 108 2011 2909 2914
125. S. Wilop, S. von Hobe, M. Crysandt, A. Esser, R. Osieka, and E. Jost Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy J. Cancer Res. Clin. Oncol. 135 2009 1429 1435
126. D. Keizman, P. Huang, M.A. Eisenberger, R. Pili, J.J. Kim, E.S. Antonarakis, H. Hammers, and M.A. Carducci Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination Eur. J. Cancer 47 2011 1955 1961
127. Y. Nakai, H. Isayama, H. Ijichi, T. Sasaki, N. Takahara, Y. Ito, S. Matsubara, R. Uchino, H. Yagioka, T. Arizumi, T. Hamada, K. Miyabayashi, S. Mizuno, K. Yamamoto, H. Kogure, N. Yamamoto, K. Hirano, N. Sasahira, K. Tateishi, M. Tada, and K. Koike A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2 Invest. New Drugs 31 2013 1294 1299
128. J.H. Kim, W.S. Park, B.C. Shin, and H.-J. Kuh Pentoxifylline enhanced the efficacy of gemcitabine by improving drug delivery via modulating CTGF-mediated fibrosis in pancreatic tumor xenografts Brekthroughs in Basic and Translational Cancer Research, AACR/JCR Joint Conference, Hyatt Regency Maui HI 2013
129. Y. Chen, Y. Huang, T. Reiberger, A.M. Duyverman, P. Huang, R. Samuel, L. Hiddingh, S. Roberge, C. Koppel, G.Y. Lauwers, A.X. Zhu, R.K. Jain, and D.G. Duda Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice Hepatology 59 2014 1435 1447
130. K.P. Olive Update in IPI-926-03 trial http://www.olivelab.org/ipi-926-03.html (Accessed March 14, 2014)
131. P.P. Karmali, V.R. Kotamraju, M. Kastantin, M. Black, D. Missirlis, M. Tirrell, and E. Ruoslahti Targeting of albumin-embedded paclitaxel nanoparticles to tumors Nanomedicine 5 2009 73 82
132. K.N. Sugahara, T. Teesalu, P.P. Karmali, V.R. Kotamraju, L. Agemy, D.R. Greenwald, and E. Ruoslahti Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 328 2010 1031 1035
133. L. Roth, L. Agemy, V.R. Kotamraju, G. Braun, T. Teesalu, K.N. Sugahara, J. Hamzah, and E. Ruoslahti Transtumoral targeting enabled by a novel neuropilin-binding peptide Oncogene 31 2012 3754 3763
134. H.-B. Pang, G.B. Braun, T. Friman, P. Aza-Blanc, M.E. Ruidiaz, K.N. Sugahara, T. Teesalu, and E. Ruoslahti The CendR pathway: a novel cell penetration and transcytosis pathway regulated by nutrient availability Proceedings of the 105th Annual Meeting of the AACR; April 5-9 2014 AACR San Diego, CA
135. F. Marcucci, and A. Corti How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs Adv. Drug Deliv. Rev. 64 2012 53 68
136. J. Wang, Z. Lu, Y. Gao, M.G. Wientjes, and J.L. Au Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming Nanomedicine (Lond.) 6 2011 1605 1620
137. J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
138. L.A. Liotta, U.P. Thorgeirsson, and S. Garbisa Role of collagenases in tumor cell invasion Cancer Metastasis Rev. 1 1982 277 288
139. B. Delpech, A. Laquerriere, C. Maingonnat, P. Bertrand, and P. Freger Hyaluronidase is more elevated in human brain metastases than in primary brain tumours Anticancer Res. 22 2002 2423 2427
140. R.K. Jain, D.G. Duda, J.W. Clark, and J.S. Loeffler Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat. Clin. Pract. Oncol. 3 2006 24 40
141. C.G. Willett, Y. Boucher, D.G. Duda, E. di Tomaso, L.L. Munn, R.T. Tong, S.V. Kozin, L. Petit, R.K. Jain, D.C. Chung, D.V. Sahani, S.P. Kalva, K.S. Cohen, D.T. Scadden, A.J. Fischman, J.W. Clark, D.P. Ryan, A.X. Zhu, L.S. Blaszkowsky, P.C. Shellito, M. Mino-Kenudson, and G.Y. Lauwers Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients J. Clin. Oncol. 23 2005 8136 8139
142. A.J. Leu, D.A. Berk, A. Lymboussaki, K. Alitalo, and R.K. Jain Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation Cancer Res. 60 2000 4324 4327
143. T.P. Padera, A. Kadambi, E. di Tomaso, C.M. Carreira, E.B. Brown, Y. Boucher, N.C. Choi, D. Mathisen, J. Wain, E.J. Mark, L.L. Munn, and R.K. Jain Lymphatic metastasis in the absence of functional intratumor lymphatics Science 296 2002 1883 1886
144. S. Kashiwagi, K. Tsukada, L. Xu, J. Miyazaki, S.V. Kozin, J.A. Tyrrell, W.C. Sessa, L.E. Gerweck, R.K. Jain, and D. Fukumura Perivascular nitric oxide gradients normalize tumor vasculature Nat. Med. 14 2008 255 257
145. S.N. Thomas, E. Vokali, A.W. Lund, J.A. Hubbell, and M.A. Swartz Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response Biomaterials 35 2014 814 824
146. Y. Huang, S. Goel, D.G. Duda, D. Fukumura, and R.K. Jain Vascular normalization as an emerging strategy to enhance cancer immunotherapy Cancer Res. 73 2013 2943 2948
147. G. Wieers, N. Demotte, D. Godelaine, and P. Van der Bruggen Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines Cancers (Basel) 3 2011 2904 2954
148. D.J. Irvine, M.A. Swartz, and G.L. Szeto Engineering synthetic vaccines using cues from natural immunity Nat. Mater. 12 2013 978 990
149. R.A. Madan, J.L. Gulley, T. Fojo, and W.L. Dahut Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression Oncologist 15 2010 969 975
150. C.A. Corzo, T. Condamine, L. Lu, M.J. Cotter, J.I. Youn, P. Cheng, H.I. Cho, E. Celis, D.G. Quiceno, T. Padhya, T.V. McCaffrey, J.C. McCaffrey, and D.I. Gabrilovich HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment J. Exp. Med. 207 2010 2439 2453
151. J.J. Moon, B. Huang, and D.J. Irvine Engineering nano- and microparticles to tune immunity Adv. Mater. 24 2012 3724 3746
152. S. Stapleton, M. Milosevic, C. Allen, J. Zheng, M. Dunne, I. Yeung, and D.A. Jaffray A mathematical model of the enhanced permeaility and retention effect for liposome transport in solid tumors PLoS One 8 2013 e81157